newsfilter
← Latest News
Business Wire·

Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022

Conference call to take place at 8:30 a.m. ET Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today